A systematic review and meta-analysis of endovascular versus open surgical repair for the traumatic ruptured thoracic aorta.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
01 2020
Historique:
received: 15 12 2018
accepted: 08 05 2019
pubmed: 23 7 2019
medline: 17 6 2020
entrez: 23 7 2019
Statut: ppublish

Résumé

The purpose of this study was to compare clinical outcomes between open repair and thoracic endovascular aortic repair (TEVAR) in traumatic ruptured thoracic aorta. A comprehensive search was undertaken of the four major databases (PubMed, Embase, Scopus, and Ovid) to identify all published data comparing open vs endovascular repair. Databases were evaluated to July 2018. Odds ratios (ORs), weighted mean differences, or standardized mean differences and their 95% confidence intervals (CIs) were analyzed. The primary outcomes were stroke, paraplegia, and 30-day mortality rates; secondary outcomes were requirement for reintervention and 1-year and five-year mortality rates. A total of 1968 patients were analyzed in 21 articles. TEVAR was performed in 29% (n = 578) and open repair in 71% (n = 1390). TEVAR and open repair did not differ in the mean age of patients (42.1 ± 14 years vs 44.1 ± 14 years; P = .48). There was no difference in duration of intensive care and total hospital stay between TEVAR and open repair groups (12.7 ± 11.1 days vs 12.6 ± 8 days [P = .35] and 27.5 ± 14.6 days vs 25.9 ± 11 days [P = .80], respectively). Similarly, no statistically significant difference in postoperative paraplegia or stroke rate was noted between TEVAR and open repair (1.4% vs 2.3% [OR, 1.27; 95% CI, 0.59-2.70; P = .54] and 1% vs 0.5% [OR, 0.63; 95% CI, 0.18-2.18; P = .46]). Lower 30-day and 1-year mortality was noted in TEVAR (7.9% vs 20% [OR, 2.94; 95% CI, 1.92-4.49; P < .00001] and 8.7% vs 17% [OR, 2.11; 95% CI, 0.99-4.52; P = .05]). There was no difference in 5-year mortality (23% vs 17%; OR, 0.07; 95% CI, -0.07 to 0.20; P = .33). However, there was a higher rate of reintervention at 1 year in the endovascular group (0% vs 6%; OR, 0.17; 95% CI, 0.03-0.96; P = .04). TEVAR carries lower in-hospital mortality and provides satisfactory perioperative outcomes compared with open repair in traumatic ruptured thoracic aorta. It also provides a favorable 1-year survival at the expense of higher reintervention rates.

Identifiants

pubmed: 31327611
pii: S0741-5214(19)31230-3
doi: 10.1016/j.jvs.2019.05.011
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

270-282

Informations de copyright

Copyright © 2019 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Amer Harky (A)

Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom; School of Medicine, University of Liverpool, Liverpool, United Kingdom. Electronic address: aaharky@gmail.com.

David Bleetman (D)

Department of Cardiac Surgery, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.

Jeffrey S K Chan (JSK)

Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.

Peter Eriksen (P)

School of Medicine, University of Liverpool, Liverpool, United Kingdom.

Grace Chaplin (G)

School of Medicine, University of Liverpool, Liverpool, United Kingdom.

Beverly MacCarthy-Ofosu (B)

School of Medicine, University of Liverpool, Liverpool, United Kingdom.

Thomas Theologou (T)

Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.

Shirish Ambekar (S)

Department of Cardiac Surgery, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.

Neil Roberts (N)

Department of Cardiac Surgery, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.

Aung Oo (A)

Department of Cardiac Surgery, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH